Аннотация:
The article presents a current view on management of a rare form of papillomavirus infection (PVI) -giant condyloma of Buschke and Löwenstein. A significant problem of this pathology is conditioned by a recurrent character of tumour. After adequate operative treatment, relapses (sometimes fulminant) of the carcinoma-like process are not rare, therefore, post-operative antiviral therapy is an integral and essential component of complex treatment of patients with a Buschke-Löwenstein tumour. In a wide range of antiviral medications, Inosine pranobex (IP) is regarded as a drug of choice for treatment and prevention of PVI relapses. For these purposes, IP (Groprinosin) is administered 3 g/day (2 tablets 3 times daily) for 28 days with further recommendations to repeat the course three times (3 g/day - 28 days) with one-month intervals.
Давыдов А. И. Александр Ильгизирович 1961-
Лебедев В. А. Владимир Александрович 1955-
Шахламова М. Н. Марина Николаевна 1959-
Davy'dov A. I. Aleksandr Il`gizirovich 1961-
Lebedev V. A. Vladimir Aleksandrovich 1955-
Shakhlamova M. N. Marina Nikolaevna 1959-
Giant condyloma of Buschke and Löwenstein: A choice of post-operative therapy
Текст визуальный непосредственный
Вопросы гинекологии, акушерства и перинатологии
ООО "Издательство "Династия"
Т. 16, Вып. 4 С. 76-80
2017
Статья
Giant condyloma acumunatum of Buschke and Löwenstein Groprinosin Human papilloma virus Inosine pranobex
The article presents a current view on management of a rare form of papillomavirus infection (PVI) -giant condyloma of Buschke and Löwenstein. A significant problem of this pathology is conditioned by a recurrent character of tumour. After adequate operative treatment, relapses (sometimes fulminant) of the carcinoma-like process are not rare, therefore, post-operative antiviral therapy is an integral and essential component of complex treatment of patients with a Buschke-Löwenstein tumour. In a wide range of antiviral medications, Inosine pranobex (IP) is regarded as a drug of choice for treatment and prevention of PVI relapses. For these purposes, IP (Groprinosin) is administered 3 g/day (2 tablets 3 times daily) for 28 days with further recommendations to repeat the course three times (3 g/day - 28 days) with one-month intervals.